V. N. Shabrov
V. N. Shabrov has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Yu. A. Dzhurko
Quinta-Analytica Yaroslavl LLC
5 shared publications - A. V. Kapashin
Valenta Pharm JSC
4 shared publications - Aleksander A. Globenko
Valenta Pharm JSC
4 shared publications - Maksim A. Pasko
Valenta Pharm JSC
4 shared publications - L. N. Schitov
Quinta-Analytica Yaroslavl LLC
3 shared publications - A. I. Bashkatova
Valenta Pharm JSC
2 shared publications
Latest Publications
- 5 September 2026
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 71 (5-6) , 34-44
Pharmacokinetic Parameters of a Combination Drug Containing Imidazolyl Ethylamide of Pentanedioic Acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] Malonic Acid Diamide in Healthy Volunteers
The aim of the study was to evaluate the pharmacokinetic parameters of escalating doses of a combination drug containing imidazolyl ethylamide of pentanedioic acid (IPA) and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] malonic acid diamide (XС9) in healthy volunteers. Material and methods . A phase I clinical study was conducted to investigate the pharmacokinetic parameters of the combination drug IPA + XС9 after single and subsequent multiple oral administration in healthy volunteers. Healthy volunteers were enrolled sequentially into three dose cohorts. Volunteers in Cohort 1 ( n = 6) received IPA + XС9 capsules containing 90 mg of IPA and 5 mg of XС9 (90 mg + 5 mg); volunteers in Cohort 2 ( n = 6) received capsules containing 90 mg IPA + 10 mg XC9 (90 mg + 10 mg); and volunteers in Cohort 3 ( n = 12) received capsules containing 90 mg IPA + 20 mg XC9 (90 mg + 20 mg). During the single-dose period, volunteers received one IPA + XC9 capsule corresponding to their dose cohort. Progression to multiple dosing and dose escalation were permitted only after the independent data monitoring committee (IDMC) reviewed the safety data. The washout period between the single-dose and multiple-dose periods was at least 7 days and no more than 21 days. Blood and urine samples were collected to determine the concentrations of the study drug’s active substances, IPA and XC9. Quantification of the active substances in plasma and urine was performed by high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS). Results . During the singledose period, a slight dose-dependent effect of XC9 on the plasma pharmacokinetic parameters of IPA was observed. At the highest studied dose of IPA + XС9 (90 mg + 20 mg), the C max and AUC 0–t for IPA were 301.37 ± 89.28 ng/mL and 1297.707 ± 469.535 ng × h/mL, respectively. During the single-dose period, the systemic exposure to XС9 in plasma increased in a dose-dependent manner. The highest C max and AUC 0–t values were observed at the 20 mg dose of XС9: 22.171 ± 8.644 ng/mL and 170.713 ± 48.346 ng × h/mL for C max and AUC 0–t , respectively. During the multiple-dose period, the C max, ss and AUC 0–τ for IPA after administration of the study drug at the 90 mg + 20 mg dose were 305.38 ± 120.43 ng/mL and 1426.108 ± 526.010 ng × h/mL, respectively, showing a weak dependence on the XС9 dose. The C max , ss and AUC 0–τ for XC9 at the maximum dose were 31.694 ± 8.491 ng/mL and 215.106 ± 59.871 ng × h/mL, respectively, demonstrating a dose-dependent increase. The pharmacokinetic parameters Ae (0–t) and R max , which reflect urinary excretion and maximum excretion rate, respectively, after a single dose of the study drug at the maximum dose were as follows: for IPA, 31390.317 ± 12193.271 µg and 5189.714 ± 2321.748 µg/h; and for XС9, 1054301.250 ± 452137.325 ng and 130015.240 ± 51728.662 ng/h. Regardless of the XС9 dose, the renal clearance of IPA remained constant during single dosing, ranging from 24 to 28 L/h, whereas the renal clearance of XС9 decreased with increasing doses (from 11.308 ± 4.111 L/h to 6.125 ± 1.430 L/h). In Cohort 3, during the multiple-dose period of IPA + XС9, the Ae (0–t) and R max values for IPA were 29563.529 ± 13674.235 µg and 4119.161 ± 2231.369 µg/h, and for XС9, they were 1671113.167 ± 733115.091 ng and 172748.875 ± 96684.186 ng/h, respectively. During the multiple-dose period, IPA renal clearance remained constant, ranging from 19 to 22 L/h, whereas XC9 renal clearance decreased with increasing doses. Conclusion . The study evaluated the plasma and urinary pharmacokinetics of IPA and XС9. A weak increase in IPA exposure was observed as the XС9 dose increased. Systemic exposure to XС9 increased in a dose-dependent manner in both the single-dose and multiple-dose periods. Regardless of the XС9 dose, the renal clearance of IPA remained constant, whereas the renal clearance of XС9 decreased with increasing doses. The results showed no significant pharmacokinetic interaction between IPA and XС9. Thus, the investigated combination of active substances meets current requirements for combination drug products.
- 5 September 2026
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 71 (5-6) , 34-44
Pharmacokinetic Parameters of a Combination Drug Containing Imidazolyl Ethylamide of Pentanedioic Acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] Malonic Acid Diamide in Healthy Volunteers
The aim of the study was to evaluate the pharmacokinetic parameters of escalating doses of a combination drug containing imidazolyl ethylamide of pentanedioic acid (IPA) and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] malonic acid diamide (XС9) in healthy volunteers. Material and methods . A phase I clinical study was conducted to investigate the pharmacokinetic parameters of the combination drug IPA + XС9 after single and subsequent multiple oral administration in healthy volunteers. Healthy volunteers were enrolled sequentially into three dose cohorts. Volunteers in Cohort 1 ( n = 6) received IPA + XС9 capsules containing 90 mg of IPA and 5 mg of XС9 (90 mg + 5 mg); volunteers in Cohort 2 ( n = 6) received capsules containing 90 mg IPA + 10 mg XC9 (90 mg + 10 mg); and volunteers in Cohort 3 ( n = 12) received capsules containing 90 mg IPA + 20 mg XC9 (90 mg + 20 mg). During the single-dose period, volunteers received one IPA + XC9 capsule corresponding to their dose cohort. Progression to multiple dosing and dose escalation were permitted only after the independent data monitoring committee (IDMC) reviewed the safety data. The washout period between the single-dose and multiple-dose periods was at least 7 days and no more than 21 days. Blood and urine samples were collected to determine the concentrations of the study drug’s active substances, IPA and XC9. Quantification of the active substances in plasma and urine was performed by high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS). Results . During the singledose period, a slight dose-dependent effect of XC9 on the plasma pharmacokinetic parameters of IPA was observed. At the highest studied dose of IPA + XС9 (90 mg + 20 mg), the C max and AUC 0–t for IPA were 301.37 ± 89.28 ng/mL and 1297.707 ± 469.535 ng × h/mL, respectively. During the single-dose period, the systemic exposure to XС9 in plasma increased in a dose-dependent manner. The highest C max and AUC 0–t values were observed at the 20 mg dose of XС9: 22.171 ± 8.644 ng/mL and 170.713 ± 48.346 ng × h/mL for C max and AUC 0–t , respectively. During the multiple-dose period, the C max, ss and AUC 0–τ for IPA after administration of the study drug at the 90 mg + 20 mg dose were 305.38 ± 120.43 ng/mL and 1426.108 ± 526.010 ng × h/mL, respectively, showing a weak dependence on the XС9 dose. The C max , ss and AUC 0–τ for XC9 at the maximum dose were 31.694 ± 8.491 ng/mL and 215.106 ± 59.871 ng × h/mL, respectively, demonstrating a dose-dependent increase. The pharmacokinetic parameters Ae (0–t) and R max , which reflect urinary excretion and maximum excretion rate, respectively, after a single dose of the study drug at the maximum dose were as follows: for IPA, 31390.317 ± 12193.271 µg and 5189.714 ± 2321.748 µg/h; and for XС9, 1054301.250 ± 452137.325 ng and 130015.240 ± 51728.662 ng/h. Regardless of the XС9 dose, the renal clearance of IPA remained constant during single dosing, ranging from 24 to 28 L/h, whereas the renal clearance of XС9 decreased with increasing doses (from 11.308 ± 4.111 L/h to 6.125 ± 1.430 L/h). In Cohort 3, during the multiple-dose period of IPA + XС9, the Ae (0–t) and R max values for IPA were 29563.529 ± 13674.235 µg and 4119.161 ± 2231.369 µg/h, and for XС9, they were 1671113.167 ± 733115.091 ng and 172748.875 ± 96684.186 ng/h, respectively. During the multiple-dose period, IPA renal clearance remained constant, ranging from 19 to 22 L/h, whereas XC9 renal clearance decreased with increasing doses. Conclusion . The study evaluated the plasma and urinary pharmacokinetics of IPA and XС9. A weak increase in IPA exposure was observed as the XС9 dose increased. Systemic exposure to XС9 increased in a dose-dependent manner in both the single-dose and multiple-dose periods. Regardless of the XС9 dose, the renal clearance of IPA remained constant, whereas the renal clearance of XС9 decreased with increasing doses. The results showed no significant pharmacokinetic interaction between IPA and XС9. Thus, the investigated combination of active substances meets current requirements for combination drug products.
- 30 October 2025
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 70 (9-10)
Study of the Pharmacokinetics, Tolerability, and Safety of Fixed-Dose Combinations of Gramicidin S and Cetylpyridinium Chloride
The aim of the study was to compare the safety, tolerability, and pharmacokinetic profile of Grammidin® neo, lozenges, and Grammidin®, a metered-dose topical spray, manufactured by Valenta Pharm JSC, Russia, following single-dose administration in healthy volunteers. Material and methods. An open-label, randomized, two-period crossover study was conducted to evaluate the safety, tolerability, and pharmacokinetic parameters of Grammidin® (metered-dose topical spray) compared to Grammidin® neo (lozenges). Healthy volunteers were randomized into two sequence groups according to the order of drug administration in periods I and II of the study. In group 1, subjects received 1 lozenge of Grammidin® neo during period I. In period II, the same volunteers received 4 sprays of Grammidin® to the oral and pharyngeal mucosa applied by the researcher. Group 2 subjects received the study medications in reverse order. The washout period between administrations of the study drugs was 7 days. Concentrations of the active pharmaceutical substances were determined in plasma using high-performance liquid chromatography–tandem mass spectrometry (LC-MS/MS) with prior analyte extraction from the biological matrix. The study included ongoing monitoring of vital signs, as well as assessments of laboratory parameters (complete blood count, serum biochemistry, and urinalysis) and standard 12-lead ECG recordings. All subject-reported complaints, as well as any abnormalities or clinically significant deviations from reference ranges in general health status, laboratory findings, or ECG parameters were documented and categorized by the researcher as adverse events (AEs ). Results . Of the 16 volunteers who received the study drugs in periods I and II, only 6 demonstrated plasma concentrations of gramicidin S and cetylpyridinium chloride above the lower limit of quantification (LLOQ) at isolated time points. Due to the insufficient number of measurable concentrations, pharmacokinetic parameters could not be reliably calculated. During the study, one mild adverse event (AE) was reported in a single volunteer — pain at the catheter insertion site. The relationship between this AE and study drug administration was assessed by the researcher as indeterminate. This AE resolved spontaneously without any therapeutic intervention. Conclusion . Topical administration of gramicidin S and cetylpyridinium chloride to the oropharyngeal mucosa resulted in minimal systemic exposure, making pharmacokinetic characterization unfeasible. The fixed-dose combination was safe and well tolerated in all participants, with no meaningful differences observed between the lozenge and spray formulations.
- 30 October 2025
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 70 (9-10)
Study of the Pharmacokinetics, Tolerability, and Safety of Fixed-Dose Combinations of Gramicidin S and Cetylpyridinium Chloride
The aim of the study was to compare the safety, tolerability, and pharmacokinetic profile of Grammidin® neo, lozenges, and Grammidin®, a metered-dose topical spray, manufactured by Valenta Pharm JSC, Russia, following single-dose administration in healthy volunteers. Material and methods. An open-label, randomized, two-period crossover study was conducted to evaluate the safety, tolerability, and pharmacokinetic parameters of Grammidin® (metered-dose topical spray) compared to Grammidin® neo (lozenges). Healthy volunteers were randomized into two sequence groups according to the order of drug administration in periods I and II of the study. In group 1, subjects received 1 lozenge of Grammidin® neo during period I. In period II, the same volunteers received 4 sprays of Grammidin® to the oral and pharyngeal mucosa applied by the researcher. Group 2 subjects received the study medications in reverse order. The washout period between administrations of the study drugs was 7 days. Concentrations of the active pharmaceutical substances were determined in plasma using high-performance liquid chromatography–tandem mass spectrometry (LC-MS/MS) with prior analyte extraction from the biological matrix. The study included ongoing monitoring of vital signs, as well as assessments of laboratory parameters (complete blood count, serum biochemistry, and urinalysis) and standard 12-lead ECG recordings. All subject-reported complaints, as well as any abnormalities or clinically significant deviations from reference ranges in general health status, laboratory findings, or ECG parameters were documented and categorized by the researcher as adverse events (AEs ). Results . Of the 16 volunteers who received the study drugs in periods I and II, only 6 demonstrated plasma concentrations of gramicidin S and cetylpyridinium chloride above the lower limit of quantification (LLOQ) at isolated time points. Due to the insufficient number of measurable concentrations, pharmacokinetic parameters could not be reliably calculated. During the study, one mild adverse event (AE) was reported in a single volunteer — pain at the catheter insertion site. The relationship between this AE and study drug administration was assessed by the researcher as indeterminate. This AE resolved spontaneously without any therapeutic intervention. Conclusion . Topical administration of gramicidin S and cetylpyridinium chloride to the oropharyngeal mucosa resulted in minimal systemic exposure, making pharmacokinetic characterization unfeasible. The fixed-dose combination was safe and well tolerated in all participants, with no meaningful differences observed between the lozenge and spray formulations.
- Open Access
- 20 July 2023
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 2,p. 37-44
Study of the effect of food on the bioavailability, safety and tolerability of Aterixen® 100 mg tablet in healthy volunteers
The aim. The primary objective of the study was to evaluate the effect of food on the bioavailability of Aterixen® 100 mg tablet after single oral dose under fasting or fed conditions. The secondary objective was to evaluate the pharmacokinetic parameters, safety, and tolerability of Aterixen® 100 mg tablet after single oral dose under fasting or fed conditions. Materials and methods. Healthy male and female volunteers aged 18 to 45 years were included in the study. Due to lack of data about intra-individual variability of the main pharmacokinetic parameters of the active substance in Aterixen® (XC221GI, 1-[2-(1-Methylimidazol-4-yl)-ethyl]perhydroazin-2,6-dione), an adaptive group sequential approach was used in the study. At Stage I, 24 volunteers were randomized into 2 groups (12 in each group): Group 1 (sequence AAB) received treatment A (administration of the drug under fasting conditions) during period I, treatment A during period II and treatment B (administration of the drug under fed conditions) during period III, Group 2 (sequence BBA) received therapy B during period I, therapy B during period II, and therapy A during period III. In each study period, serial blood samples were collected before and throughout 12 h after administration of the study drug. The quantification of the active substance XC221GI in plasma samples was performed using a validated high-performance liquid chromatography method with mass spectrometric detection. Safety evaluation was performed on the basis of frequency and severity of adverse events (AEs) and serious adverse events (SAEs), which were registered based on complaints, physical examination, laboratory tests, and electrocardiography (ECG). Drug tolerability was evaluated in terms of proportion of volunteers who prematurely discontinued participation in the study due to AE/SAE. Results. 24 randomized volunteers completed the study in compliance with the approved study protocol. The averaged pharmacokinetic curves profiles of XC221GI had similar shapes under fasting and fed conditions. Confidence intervals for the ratio of the geometric means for the primary parameters (AUC(0-t) and Cmax) of XC221GI and AUC(0-∞) were within the 80-125 % acceptance interval, while a small in absolute value, but statistically significant differences were noted in time until Cmax is reached. Throughout the study, 2 volunteers reported AEs (low RBC count, low hemoglobin concentration, and low hematocrit value) after receiving the study drug under fed conditions. All reported AEs were mild. The relationship between AEs and the study drug product was assessed by investigator as doubtful. Conclusion. The results of this study indicate that food does not affect the bioavailability of Aterixen® 100 mg, tablets, and the single oral dose of 100 mg was safe and well tolerated by healthy volunteers.
- 20 July 2023
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 2,p. 37-44
Open AccessStudy of the effect of food on the bioavailability, safety and tolerability of Aterixen® 100 mg tablet in healthy volunteers
The aim. The primary objective of the study was to evaluate the effect of food on the bioavailability of Aterixen® 100 mg tablet after single oral dose under fasting or fed conditions. The secondary objective was to evaluate the pharmacokinetic parameters, safety, and tolerability of Aterixen® 100 mg tablet after single oral dose under fasting or fed conditions. Materials and methods. Healthy male and female volunteers aged 18 to 45 years were included in the study. Due to lack of data about intra-individual variability of the main pharmacokinetic parameters of the active substance in Aterixen® (XC221GI, 1-[2-(1-Methylimidazol-4-yl)-ethyl]perhydroazin-2,6-dione), an adaptive group sequential approach was used in the study. At Stage I, 24 volunteers were randomized into 2 groups (12 in each group): Group 1 (sequence AAB) received treatment A (administration of the drug under fasting conditions) during period I, treatment A during period II and treatment B (administration of the drug under fed conditions) during period III, Group 2 (sequence BBA) received therapy B during period I, therapy B during period II, and therapy A during period III. In each study period, serial blood samples were collected before and throughout 12 h after administration of the study drug. The quantification of the active substance XC221GI in plasma samples was performed using a validated high-performance liquid chromatography method with mass spectrometric detection. Safety evaluation was performed on the basis of frequency and severity of adverse events (AEs) and serious adverse events (SAEs), which were registered based on complaints, physical examination, laboratory tests, and electrocardiography (ECG). Drug tolerability was evaluated in terms of proportion of volunteers who prematurely discontinued participation in the study due to AE/SAE. Results. 24 randomized volunteers completed the study in compliance with the approved study protocol. The averaged pharmacokinetic curves profiles of XC221GI had similar shapes under fasting and fed conditions. Confidence intervals for the ratio of the geometric means for the primary parameters (AUC(0-t) and Cmax) of XC221GI and AUC(0-∞) were within the 80-125 % acceptance interval, while a small in absolute value, but statistically significant differences were noted in time until Cmax is reached. Throughout the study, 2 volunteers reported AEs (low RBC count, low hemoglobin concentration, and low hematocrit value) after receiving the study drug under fed conditions. All reported AEs were mild. The relationship between AEs and the study drug product was assessed by investigator as doubtful. Conclusion. The results of this study indicate that food does not affect the bioavailability of Aterixen® 100 mg, tablets, and the single oral dose of 100 mg was safe and well tolerated by healthy volunteers.
- 21 June 2023
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 45 (2)
Effect of food intake on pharmacokinetic profile of the new original drug «Respoxyton» in healthy volunteers
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить влияние приема пищи на биодоступность препарата «Респокситон» (таблетки, покрытые пленочной оболочкой, 10 мг) (АО «Валента Фарм», Россия), разрабатываемого по показанию «сухой непродуктивный кашель на фоне острой респираторной вирусной инфекции и острого бронхита», а также оценить его фармакокинетические параметры, безопасность и переносимость после однократного приема внутрь в дозе 20 мг (две таблетки) здоровыми добровольцами натощак и после приема пищи. МАТЕРИАЛ И МЕТОДЫ Проведено открытое рандомизированное перекрестное исследование с двумя видами применения препарата (натощак и после еды), тремя периодами, двумя последовательностями приема и адаптивным двухэтапным дизайном. При разработке протокола в связи с отсутствием данных о внутрииндивидуальной вариабельности основных фармакокинетических параметров действующего вещества препарата «Респокситон» (ХС8, N-[2-(1H-Имидазол-4-ил)-этил]-6-оксо-δ-лактам) в исследовании запланирован адаптивный последовательный подход (модифицированный по E. Molins и соавт. (2017) метод Potvin типа C). После получения фармакокинетических данных на первом этапе исследования проведен промежуточный анализ данных, по результатам которого необходимость в проведении второго этапа признана нецелесообразной. Исследование состояло из периода скрининга и трех периодов исследования фармакокинетики. Длительность периода скрининга составляла не более 14 сут до приема исследуемого препарата. Длительность периодов «отмывки» между приемами препарата составляла 7 дней. Всего 26 добровольцев прошли скрининг, по результатам которого 24 добровольца рандомизированы и принимали исследуемый препарат согласно назначенной схемой рандомизации последовательности: группа «Натощак — Натощак — После еды» [Fasting-Fasting-Fed] (12 добровольцев) и группа «После еды — После еды — Натощак» [Fed-Fed-Fasting] (12 добровольцев). Все 24 добровольца завершили участие в исследовании согласно протоколу. В каждом периоде исследования у добровольцев проводили забор 17 образцов крови. Количественное определение ХС8 в образцах плазмы крови выполнено валидированным методом высокоэффективной жидкостной хроматографии с тандемным масс-спектрометрическим детектированием. РЕЗУЛЬТАТЫ Выявлено, что 90% доверительные интервалы (90% ДИ) для отношений средних геометрических значений ХС8 натощак и после еды (AUC0—t (fed)/AUC0—t (fasting); AUC0—∞ (fed)/AUC0—∞ (fasting); Cmax (fed)/Cmax (fasting)) соответствовали установленным границам биоэквивалентности 80,00—125,00%, что позволяет сделать вывод об отсутствии влияния приема пищи на биодоступность препарата «Респокситон». Во время исследования зарегистрировано 3 нежелательных явления (НЯ) у двух добровольцев. Все НЯ отмечались в периодах, когда исследуемый препарат принимался после приема пищи. Все НЯ были легкой степени выраженности, какое-либо вмешательство не потребовалось. Связь НЯ с приемом исследуемого препарата расценена как сомнительная. ЗАКЛЮЧЕНИЕ Результаты выполненного исследования позволяют сделать вывод об отсутствии влияния приема пищи на биодоступность препарата «Респокситон» (таблетки, покрытые пленочной оболочкой, 10 мг). Препарат показал хорошую безопасность и переносимость.
- 21 June 2023
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 45 (2)
Effect of food intake on pharmacokinetic profile of the new original drug «Respoxyton» in healthy volunteers
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить влияние приема пищи на биодоступность препарата «Респокситон» (таблетки, покрытые пленочной оболочкой, 10 мг) (АО «Валента Фарм», Россия), разрабатываемого по показанию «сухой непродуктивный кашель на фоне острой респираторной вирусной инфекции и острого бронхита», а также оценить его фармакокинетические параметры, безопасность и переносимость после однократного приема внутрь в дозе 20 мг (две таблетки) здоровыми добровольцами натощак и после приема пищи. МАТЕРИАЛ И МЕТОДЫ Проведено открытое рандомизированное перекрестное исследование с двумя видами применения препарата (натощак и после еды), тремя периодами, двумя последовательностями приема и адаптивным двухэтапным дизайном. При разработке протокола в связи с отсутствием данных о внутрииндивидуальной вариабельности основных фармакокинетических параметров действующего вещества препарата «Респокситон» (ХС8, N-[2-(1H-Имидазол-4-ил)-этил]-6-оксо-δ-лактам) в исследовании запланирован адаптивный последовательный подход (модифицированный по E. Molins и соавт. (2017) метод Potvin типа C). После получения фармакокинетических данных на первом этапе исследования проведен промежуточный анализ данных, по результатам которого необходимость в проведении второго этапа признана нецелесообразной. Исследование состояло из периода скрининга и трех периодов исследования фармакокинетики. Длительность периода скрининга составляла не более 14 сут до приема исследуемого препарата. Длительность периодов «отмывки» между приемами препарата составляла 7 дней. Всего 26 добровольцев прошли скрининг, по результатам которого 24 добровольца рандомизированы и принимали исследуемый препарат согласно назначенной схемой рандомизации последовательности: группа «Натощак — Натощак — После еды» [Fasting-Fasting-Fed] (12 добровольцев) и группа «После еды — После еды — Натощак» [Fed-Fed-Fasting] (12 добровольцев). Все 24 добровольца завершили участие в исследовании согласно протоколу. В каждом периоде исследования у добровольцев проводили забор 17 образцов крови. Количественное определение ХС8 в образцах плазмы крови выполнено валидированным методом высокоэффективной жидкостной хроматографии с тандемным масс-спектрометрическим детектированием. РЕЗУЛЬТАТЫ Выявлено, что 90% доверительные интервалы (90% ДИ) для отношений средних геометрических значений ХС8 натощак и после еды (AUC0—t (fed)/AUC0—t (fasting); AUC0—∞ (fed)/AUC0—∞ (fasting); Cmax (fed)/Cmax (fasting)) соответствовали установленным границам биоэквивалентности 80,00—125,00%, что позволяет сделать вывод об отсутствии влияния приема пищи на биодоступность препарата «Респокситон». Во время исследования зарегистрировано 3 нежелательных явления (НЯ) у двух добровольцев. Все НЯ отмечались в периодах, когда исследуемый препарат принимался после приема пищи. Все НЯ были легкой степени выраженности, какое-либо вмешательство не потребовалось. Связь НЯ с приемом исследуемого препарата расценена как сомнительная. ЗАКЛЮЧЕНИЕ Результаты выполненного исследования позволяют сделать вывод об отсутствии влияния приема пищи на биодоступность препарата «Респокситон» (таблетки, покрытые пленочной оболочкой, 10 мг). Препарат показал хорошую безопасность и переносимость.
- Open Access
- 1 January 2022
- Published by Euroasian Scientific and Industrial Chamber, Ltd. in International Journal of Applied and Fundamental Research (Международный журнал прикладных и фундаментальных исследований)
- No. №1 2022,p. 40-45
PHARMACOKINETICS OF OXYETHYLAMMONIUM METHYLPHENOXYACETATE IN HEALTHY VOLUNTEERS
- 1 January 2022
- Published by Euroasian Scientific and Industrial Chamber, Ltd. in International Journal of Applied and Fundamental Research (Международный журнал прикладных и фундаментальных исследований)
- No. №1 2022,p. 40-45
Open AccessPHARMACOKINETICS OF OXYETHYLAMMONIUM METHYLPHENOXYACETATE IN HEALTHY VOLUNTEERS